| Identification | Back Directory | [Name]
JW55 | [CAS]
664993-53-7 | [Synonyms]
JW55
CS-1095
JW 55; JW-55
JW 55, >=98%
Tankyrase1/2 Inhibitor IV, JW55
Tankyrase1/2 Inhibitor IV, JW55 - CAS 664993-53-7 - Calbiochem
N-[4-[[4-(4-METHOXYPHENYL)OXAN-4-YL]METHYLCARBAMOYL]PHENYL]FURAN-2-CARBOXAMIDE
N-(4-((4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-yl)MethylcarbaMoyl)phenyl)furan-2-carboxaMide
N-(4-(((4-(4-Methoxyphenyl)tetrahydro-2H-pyran-4-yl)methyl)carbamoyl)phenyl)furan-2-carboxamid
N-[4-[[[[Tetrahydro-4-(4-methoxyphenyl)-2H-pyran-4-yl]methyl]amino]carbonyl]phenyl]-2-furancarboxamide
2-Furancarboxamide, N-[4-[[[[tetrahydro-4-(4-methoxyphenyl)-2H-pyran-4-yl]methyl]amino]carbonyl]phenyl]-
JW55 N-[4-[[[[Tetrahydro-4-(4-methoxyphenyl)-2H-pyran-4-yl]methyl]amino]carbonyl]phenyl]-2-furancarboxamide | [Molecular Formula]
C25H26N2O5 | [MDL Number]
MFCD03863265 | [MOL File]
664993-53-7.mol | [Molecular Weight]
434.48 |
| Chemical Properties | Back Directory | [Melting point ]
153-155 °C | [Boiling point ]
572.6±50.0 °C(Predicted) | [density ]
1.235±0.06 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: soluble15mg/mL, clear | [form ]
powder | [pka]
12.41±0.70(Predicted) | [color ]
white to beige | [InChI]
1S/C25H26N2O5/c1-30-21-10-6-19(7-11-21)25(12-15-31-16-13-25)17-26-23(28)18-4-8-20(9-5-18)27-24(29)22-3-2-14-32-22/h2-11,14H,12-13,15-17H2,1H3,(H,26,28)(H,27,29) | [InChIKey]
ZJZWZIXSGNFWQQ-UHFFFAOYSA-N | [SMILES]
O1C=CC=C1C(NC1=CC=C(C(NCC2(C3=CC=C(OC)C=C3)CCOCC2)=O)C=C1)=O |
| Hazard Information | Back Directory | [Description]
JW 55 is an inhibitor of the PARP domain of tankyrases (TNKS) 1 and 2 (IC50s = 1.9 and 0.83 μM, respectively).1 By inhibiting TNKS1/2, JW 55 stabilizes Axin2 and increases degradation of β-catenin, inhibiting the β-catenin signaling pathway (IC50 = 470 nM).1 It has been shown to decrease canonical Wnt signaling in SW480 and HCT15 colon carcinoma cell lines and to reduce proliferation of SW480 cells in vitro.1 | [Uses]
JW-55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). Activity results in stabilization of Axin2 and increased degradation of β-catenin. JW-55 inhibits the β-catenin signaling pathway. Also shown to decrease canonical Wnt signaling in SW480 and HCT-15 colon carcinoma cell lines. JW-55 reduces cell cycle progression and proliferation in SW480 cells in vitro. | [Definition]
ChEBI: N-[4-[[[4-(4-methoxyphenyl)-4-oxanyl]methylamino]-oxomethyl]phenyl]-2-furancarboxamide is a member of furans and an aromatic amide. | [in vivo]
JW 55 (100 mg/kg, orally) reduces tumor development in conditional Apc knockout mice. JW55 reduces XWnt8-induced axis duplication inXenopus embryos and Tamoxifen-induced polyposis formation in conditional APC mutant mice[1]. | [IC 50]
TNKS2: 0.83 μM (IC50); TNKS1: 1.9 μM (IC50) | [storage]
Store at 4°C | [References]
[1] waaler j, machon o, tumova l, dinh h, korinek v, wilson sr, paulsen je, pedersen nm, eide tj, machonova o, gradl d, voronkov a, von kries jp, krauss s. a novel tankyrase inhibitor decreases canonical wnt signaling in colon carcinoma cells and reduces tumor growth in conditional apc mutant mice. cancer res. 2012;72(11):2822-32. |
|
| Company Name: |
J & K SCIENTIFIC LTD.
|
| Telephone: |
18210857532 18210857532 |
| Website: |
https://www.jkchemical.com |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|